Paul Workman Honored with 2024 International Chemical Biology Society Global Lectureship Award

Paul Workman was recognised with the 2024 International Chemical Biology Society Global Lectureship Award.

Paul Workman is Harrap Professor of Pharmacology and Therapeutics at The Institute of Cancer Research.

Paul Workman the was Chief Executive and President of The Institute of Cancer Research (ICR) from 2014 to 2021.

Professor Paul Workman is a passionate advocate of personalised molecular medicine.

Additionally, He was instrumental in the discovery at ICR of fadraciclib, a selective CDK9/2 inhibitor that shows promise in models of MYCN-driven paediatric neuroblastoma and has now progressed into a first-in-child clinical trial.

Professor Workman completed his BSc in Biochemistry at the University of Leicester UK (1973) and his PhD in Cancer Pharmacology at the University of Leeds UK (1977).

In 1997, Professor Workman moved to ICR to take over and build up what is now the Centre for Cancer Drug Discovery, and held the position of unit Director until January 2016.

He has received numerous awards and honors, some of them include:

Fellow of the Royal Society (elected in 2016), UICC ICRETT Fellow, Cancer Research UK Life Fellow, Fellow of the Academy of Medical Sciences, Fellow of the Royal Society of Chemistry, Fellow of the Royal Society of Medicine, Fellow of the Society of Biology and Member of the Faculty of 1000.

Professor Workman has received the European School of Oncology Award for Excellence in Oncology Research, NDDO Award for Cancer Drug Development, ICON Distinguished Lecture, Bruce Cain Memorial Lecture of the New Zealand Cancer Society and NCRI/BACR Tom Connors Award Lecture.

For more posts like this, visit oncodaily.com